A type of immune cell targeting the Epstein-Barr virus may play a key role in driving multiple sclerosis (MS), a study found.

MS pain is the uninvited guest you can't turn away, columnist Desiree Lama writes. Listening to your body is the key to ...

TG Therapeutics is gearing up for a new clinical trial, dubbed ULTIMATE, to test Briumvi in children and adolescents with ...

Tolebrutinib failed to lower disability progression risk in primary progressive MS in a Phase 3 trial, with data shown at ...

Teva Canada and Novartis Canada are collaborating to ensure continued access to Mayzent for people with active SPMS in Canada ...

Scientists at the 2026 ACTRIMS forum meet to assess current approaches and explore new directions for MS research and care.

After up to three years on GA Depot, most people with PPMS have not experienced any disability progression, according to new ...

In people with early MS, diet may correlate with biological aging and the development of disease-related disability, study ...

Researchers developed a mouse model of multiple sclerosis that captures the features of progression independent of relapse ...

A small study suggests Mavenclad’s effectiveness in MS may be linked to how regulatory T-cells respond to treatment.

BTK inhibitors such as tolebrutinib or evobrutinib work about as well as Aubagio at preventing relapses in MS, a review of ...